Abbvie Inc., of North Chicago, and Bristol-Myers Squibb Co., of New York, are collaborating to test the combination of Abbvie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's PD-1 antibody Opdivo (nivolumab).